Leuk Lymphoma
January 2025
Multiple Myeloma Division, The John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.
Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world.
View Article and Find Full Text PDFMed Sci (Basel)
December 2024
Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Background: Esophageal cancer (EC) is the sixth leading cause of cancer-related mortality worldwide, continuing to be a significant public health concern. The purpose of this study is to assess the impact of staging and histopathology of EC on associated mortality. The study also aims to further investigate clinical characteristics, prognostic factors, and survival outcomes in patients diagnosed with EC between 2010 and 2017.
View Article and Find Full Text PDFJ Clin Oncol
December 2024
Department of Dermatology, The University of Texas-MD Anderson Cancer Center, Houston, TX.
Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).
Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.
Am J Hematol
December 2024
Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.
JAAD Case Rep
December 2024
Department of Internal Medicine, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey.
Purpose: We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).
Methods: Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle.
Eur J Haematol
December 2024
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Venetoclax, the first-in-class BCL-2 inhibitor, has shown efficacy in multiple myeloma (MM), particularly in patients with the t(11;14) translocation. This single-center retrospective analysis included MM patients treated with venetoclax from November 2017 to March 2023. Data encompassed demographics, disease characteristics, treatment regimens, and outcomes using median progression-free-survival (mPFS).
View Article and Find Full Text PDFBlood
December 2024
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States.
Interferon-alpha has activity against multiple myeloma. Modakafusp alfa is an immunocytokine comprising two attenuated interferon-alpha2b molecules and an anti-CD38 IgG4 antibody, targeting delivery of interferon-alpha to CD38+ immune and myeloma cells. This phase I/II trial (NCT03215030) enrolled patients with relapsed/refractory multiple myeloma with ≥3 prior lines of treatment and refractory to or intolerant of ≥1 proteasome inhibitor and ≥1 immunomodulatory drug.
View Article and Find Full Text PDFBone Marrow Transplant
December 2024
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Clin Lymphoma Myeloma Leuk
December 2024
City of Hope Medical Center, Duarte, CA.
Med Sci (Basel)
October 2024
Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Chronic Myelomonocytic Leukemia (CMML) is a rare and aggressive form of leukemia with characteristics of both myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDSs). This study aims to explore the clinical features, survival outcomes, and prognostic factors in CMML patients over the past 20 years using a large sample. The study data from 4124 patients diagnosed with CMML between 2000 and 2017 were sourced from the SEER database.
View Article and Find Full Text PDFBlood Adv
November 2024
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor-modified T cells (CAR-T). The optimal timing of BsAbs and biomarkers of BsAb response after CAR-T are unknown. We addressed these questions using clinical data and blood samples from patients previously treated with CAR-T treated on a phase I/II study of mosunetuzumab (clinicaltrials.
View Article and Find Full Text PDFSupport Care Cancer
November 2024
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Purpose: Despite growing research on financial toxicity among cancer survivors, large gaps remain in understanding how to intervene to minimize financial toxicity. Uptake and efficacy of interventions mitigating cancer financial toxicity, though promising, remain limited and inconsistent. To date, survivor preferences for financial toxicity interventions are underexplored.
View Article and Find Full Text PDFLancet Oncol
December 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Clin Med
October 2024
Division of Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Allogeneic stem cell transplantation (allo-SCT) has seen limited use in treating multiple myeloma (MM), despite its potential to offer long-term survival or even cure through the graft-versus-myeloma effect. Its limited application is largely due to concerns over serious complications like infections and graft-versus-host disease (GVHD). The possibility of GVHD exacerbation when CAR-T cells are administered to patients previously treated with allo-SCT remains a topic of concern.
View Article and Find Full Text PDFPatient Prefer Adherence
October 2024
Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ, USA.
Introduction: Treatment decision-making for multiple myeloma (MM) is complex. Individuals involved in decision-making may value treatment attributes differently based on their role as a patient, care partner, or physician. This study describes those attributes, and what is most important by role.
View Article and Find Full Text PDFLeukemia
December 2024
Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands.
Haematologica
September 2024
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA; Hackensack Meridian School of Medicine, Nutley, NJ, USA; Department of Oncology, Georgetown University, Washington, DC, USA; Department of Pediatrics, Hackensack University Medical Center, Hackensack, NJ.
Clin Lymphoma Myeloma Leuk
August 2024
Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ.
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by production of abnormal levels of a monoclonal immunoglobulin or plasma cell deposition that leads to end organ destruction. The disease remains incurable despite advances in combination treatments with classes of medications that include proteosome inhibitors, immunomodulating agents, monoclonal antibodies, small molecule inhibitors, alkylating agents, T-cell-based immunotherapies, and others. Checkpoint inhibitors (CKP-I), though showing robust efficacy in solid tumor and lymphoma, have had limited success as single agents in the treatment of MM.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
December 2024
John Theurer Cancer Center, Hackensack, NJ. Electronic address:
Front Oncol
August 2024
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, United States.
Background And Purpose: The aim of this study was to determine the prevalence of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation therapy (RT) plan (defined as <5 malignant lesions) and may benefit from bridging RT prior to CD19 CART.
Materials And Methods: This is a single-center, retrospective study of patients with R/R NHL who received CD19 CART from 2018 to 2022. Eligible patients had pre-apheresis radiologic studies available.
Adv Clin Exp Med
August 2024
Plasma Cell Dyscrasias Center, Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.
Background: Non-secretory multiple myeloma (NSMM) accounts for approx. 2-3% of multiple myeloma (MM) cases. Due to the rare occurrence and ineligibility of patients with NSMM to participate in clinical trials, we have limited data on treatment efficacy and the clinical course in these patients.
View Article and Find Full Text PDFNat Cancer
October 2024
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity.
View Article and Find Full Text PDFJ Hematol Oncol
August 2024
Hackensack Meridian School of Medicine, Nutley, NJ, USA.
J Clin Med
July 2024
Division of Bone Marrow Transplant and Cellular Therapy, John Theurer Cancer Center, Hackensack, NJ 07601, USA.
Allogeneic stem cell transplantation (Allo-SCT) implies that a donor and a recipient are not genetically identical. Allo-SCT is used to cure a variety of conditions, including hematologic malignancies using the graft versus tumor effect, nonmalignant hematologic, immune deficiencies, and, more recently, genetic disorders and inborn errors of metabolism. Given the immunosuppressive and myeloablative nature of some of the conditioning chemotherapy regimens used during the Allo-SCT, patients are often at high risk of infection, including viral infections affecting the gastrointestinal tract, following the transplant.
View Article and Find Full Text PDF© LitMetric 2025. All rights reserved.